Edaravone inhibits procaspase-3 denitrosylation and activation through FasL-Trx2 pathway in KA-induced seizure

Fundam Clin Pharmacol. 2020 Dec;34(6):662-670. doi: 10.1111/fcp.12556. Epub 2020 Apr 13.

Abstract

Previous studies have demonstrated that excessive free radicals play an essential role in the initiation and progression of epilepsy and that a novel exogenous free radical scavenger edaravone (Ed) exerts some neuroprotective effects on seizure-induced neuronal damage. The purpose of this study was to elucidate the possible molecular mechanisms of Ed associated with procaspase-3 denitrosylation and activation through the FasL-Trx2 pathway in seizures rats. In this study, we investigated the effects of Ed on the regulation of the combination of Fas ligand/Fas receptor and the major components of the death-inducing signaling complex (DISC) in the hippocampus of kainic acid (KA)-treated Sprague Dawley (SD) rats. Treatment with Ed can attenuate the increased expression of FasL induced by KA and prevent procaspase-3 denitrosylation and activation via suppression of the FasL-Trx2 signaling pathway, which alleviates the neuronal damage in seizures. These results provide experimental evidence that Ed functions by preventing the denitrosylation and activation of procaspase-3 and that Ed acts as a therapeutic option for epilepsy.

Keywords: Fas/FasL; Trx-TrxR system; caspase-3; denitrosylation; edaravone; seizure.

MeSH terms

  • Animals
  • Caspase 3 / metabolism
  • Disease Models, Animal
  • Edaravone / pharmacology*
  • Fas Ligand Protein / metabolism
  • Kainic Acid
  • Male
  • Neuroprotective Agents / pharmacology*
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Seizures / chemically induced*
  • Signal Transduction / drug effects
  • Specific Pathogen-Free Organisms

Substances

  • Fas Ligand Protein
  • Neuroprotective Agents
  • CASP3 protein, human
  • Caspase 3
  • Edaravone
  • Kainic Acid